Abstract: Tumor associated carbohydrate antigens (TACAs) are a class of glycans with important structural and signaling functions playing a major role in cell proliferation, differentiation, and apoptosis relevant to oncology. Tumor cells expressing TACAs influence prognosis and survival of cancer patients. Careful consideration must be given to structural aspects during rational design of small molecule therapeutics that mimic the molecular topology of different classes of TACAs even though they are chemically dissimilar but functionally equivalent molecular structures.
Introduction
Structural analyses of receptors/targets provide us with an effective tool for the development of disease therapeutics.
Targeted therapies are expected to be more effective than current treatments and less harmful to normal cells. The advent of therapies based on mechanisms that target critical molecular pathways of tumors has evoked considerable interest (Green 2004 ).
There is a growing number of FDA approved monoclonal antibodies and small molecules targeting specific types of cancer suggestive of the growing relevance of this therapeutic approach. Targeted cancer therapies, also referred to as "Personalized Medicine", are being studied for use alone, in combination with other targeted therapies, and in combination with chemotherapy (Joo et al. 2013) . Targeted 
TACAs as essential biomarkers
Broadly speaking, TACAs can be divided into:
1. Glycolipids -GM1, GM2, GD2, and When these antigens are detected at the surface of breast carcinoma cells, they are usually associated with a poor prognosis and a reduced overall survival of the patients (Miles et al. 1994 ). These glycosylation changes mostly result from the modification of the expression of glycosyltransferase (GT) genes, and the level of expression of sialyltransferases has been proposed as a prognostic marker for the follow-up of breast cancer patients (Recchi et al. 1998) ( Table 1) .
TACA

Altered Pathway Comments
Mucin Type antigens
Thomsen- or serine residue known as the "Tn antigen" (Brooks et al. 2010b; Jensen et al. 1996) . ST6GAL1 (Le et al. 1992 ) and MGAT5 (Buckhaults et al. 1997) , are regulated by oncogenes.
Development of therapeutics
The development of vaccines can also be 
